Antithrombotic treatment in primary percutaneous coronary intervention

REFERENCES

• Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141:e139–e596.
   PubMed Web of Science ®Google Scholar
• Scholz KH, Maier SKG, Maier LS, et al.. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. Eur Heart J. 2018;39(13):1065–1074. DOI:10.1093/eurheartj/ehy004.
   PubMed Web of Science ®Google Scholar
• Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet. 2006;367(9510):579–588.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al.. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. DOI:10.1093/eurheartj/ehx393.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al.. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2016;133(11):1135–1147. DOI:10.1161/CIR.0000000000000336.
   PubMed Web of Science ®Google Scholar
• Chichareon P, Modolo R, Collet C, et al.. Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2019;74(21):2572–2584. DOI:10.1016/j.jacc.2019.09.038.
   PubMed Web of Science ®Google Scholar
• Cao D, Chandiramani R, Chiarito M, et al.. Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. Eur Heart J. 2021;42(4):339-351. DOI: 10.1093/eurheartj/ehaa824.
   Web of Science ®Google Scholar
• Libby P, Pasterkamp G, Crea F, et al.. Reassessing the Mechanisms of Acute Coronary Syndromes. Circ Res. 2019;124(1):150–160.
   PubMed Web of Science ®Google Scholar
• Falk E, Nakano M, Bentzon JF, et al.. Update on acute coronary syndromes: the pathologists‘ view. Eur Heart J. 2014;7(10):233–239.
   Google Scholar
• De Caterina R, Husted S, Wallentin L, et al.. Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;109(5):769–786. DOI:10.1160/TH12-06-0403.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519–1530.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Hudoba M, Massel D, et al.. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86(2):385–391.
   PubMed Web of Science ®Google Scholar
• Salter BS, Weiner MM, Trinh MA, et al.. Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review. J Am Coll Cardiol. 2016;67(21):2519–2532. DOI:10.1016/j.jacc.2016.02.073.
   PubMed Web of Science ®Google Scholar
• Silvain J, Beygui F, Barthelemy O, et al.. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;344(feb03 1):e553. DOI:10.1136/bmj.e553.
   PubMedGoogle Scholar
• Montalescot G, Zeymer U, Silvain J, et al.. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet. 2011;378(9792):693–703. DOI:10.1016/S0140-6736(11)60876-3.
   PubMed Web of Science ®Google Scholar
• Collet JP, Huber K, Cohen M, et al.. A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial). Am J Cardiol. 2013;112(9):1367–1372. DOI:10.1016/j.amjcard.2013.07.003.
   PubMed Web of Science ®Google Scholar
• Direct Thrombin Inhibitor Trialists’ Collaborative G. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients‘ data. Lancet. 2002;359(9303):294–302. DOI:10.1016/S0140-6736(02)07495-0.
   PubMed Web of Science ®Google Scholar
• Erlinge D, Omerovic E, Frobert O, et al.. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med. 2017;377(12):1132–1142. DOI:10.1056/NEJMoa1706443.
   PubMed Web of Science ®Google Scholar
• Leonardi S, Frigoli E, Rothenbuhler M, et al. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ. 2016;354:i4935.
   PubMedGoogle Scholar
• Cassese S, Byrne RA, Laugwitz KL, et al.. Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. EuroIntervention. 2015;11(2):196–203.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Toklu B, Kotwal A, et al.. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. BMJ. 2014;349(nov11 4):g6419. DOI:10.1136/bmj.g6419.
   PubMedGoogle Scholar
• Capodanno D, Gargiulo G, Capranzano P, et al.. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. Eur Heart J Acute Cardiovasc Care. 2016;5(3):253–262.
   PubMed Web of Science ®Google Scholar
• Bikdeli B, McAndrew T, Crowley A, et al.. Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. Thromb Haemost. 2020;120(2):348–362. DOI:10.1055/s-0039-1700872.
   PubMed Web of Science ®Google Scholar
• Stone GW. Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin Versus Heparin in Acute Myocardial Infarction. Transcatheter Cardiovascular Therapeutics Connect Congress Oral presentation. 2020 October 14th.
   Google Scholar
• Gargiulo G, Carrara G, Frigoli E, et al.. Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2019;73(7):758–774. DOI:10.1016/j.jacc.2018.12.023.
   PubMed Web of Science ®Google Scholar
• Rao SV, Shah R. The Fuzzy Math of Anticoagulation and Access Site: When 1 + 1 Does Not Always Equal 2. JACC Cardiovasc Interv. 2016;9(15):1532–1534.
   PubMed Web of Science ®Google Scholar
• Collaboration AT, Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. DOI:10.1136/bmj.324.7329.71.
   PubMed Web of Science ®Google Scholar
• Mayer K, Bernlochner I, Braun S, et al.. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. J Am Coll Cardiol. 2014;64(9):863–871. DOI:10.1016/j.jacc.2014.05.049.
   PubMed Web of Science ®Google Scholar
• Zeymer U, Hohlfeld T, Vom Dahl J, et al.. Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE). Thromb Haemost. 2017;117:(3):625–635. DOI:10.1160/TH16-08-0650.
   PubMed Web of Science ®Google Scholar
• Phillips DR, Charo IF, Parise LV, et al.. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 1988;71(4):831–843.
   PubMed Web of Science ®Google Scholar
• Investigators E. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689–1696.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Milluzzo RP, Angiolillo DJ. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use. Ther Adv Cardiovasc Dis. 2019;13:1753944719893274.
   Google Scholar
• Valgimigli M, Tebaldi M, Campo G, et al.. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv. 2012;5(3):268–277. DOI:10.1016/j.jcin.2012.01.006.
   PubMed Web of Science ®Google Scholar
• Gargiulo G, Esposito G, Avvedimento M, et al.. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial. Circulation. 2020;142(5):441–454. DOI:10.1161/CIRCULATIONAHA.120.046928.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Lincoff AM, Gibson CM, et al.. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361(24):2330–2341. DOI:10.1056/NEJMoa0908629.
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Hamm CW, et al.. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382(9909):1981–1992. DOI:10.1016/S0140-6736(13)61615-3.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Rivas A, et al.. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation. 2019;139(14):1661–1670. DOI:10.1161/CIRCULATIONAHA.118.038317.
   PubMed Web of Science ®Google Scholar
• Ubaid S, Ford TJ, Berry C, et al.. Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial. Thromb Haemost. 2019;119(7):1171–1181. DOI:10.1055/s-0039-1688789.
   PubMed Web of Science ®Google Scholar
• Parodi G, Valenti R, Bellandi B, et al., Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61(15):1601–1606. . DOI: 10.1016/j.jacc.2013.01.024.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Pappas C, Sfantou D, et al.. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives. J Cardiovasc Pharmacol Ther. 2018;23(1):13–22.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Kastrati A, Berger PB. Pre-treatment with P2Y 12 inhibitors in ACS patients: who, when, why, and which agent?. Eur Heart J. 2016;37(16):1284–1295.
   PubMed Web of Science ®Google Scholar
• Bellemain-Appaix A, O’Connor SA, Silvain J, et al.. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA. 2012;308(23):2507–2516. DOI:10.1001/jama.2012.50788.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Hof AW VT, Lapostolle F, et al.. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371(11):1016–1027. DOI:10.1056/NEJMoa1407024.
   PubMed Web of Science ®Google Scholar
• Milluzzo RP, Franchina GA, Capodanno D, et al.. Selatogrel, a novel P2Y 12 inhibitor: a review of the pharmacology and clinical development. Expert Opin Investig Drugs. 2020;29(6):537–546.
   PubMed Web of Science ®Google Scholar
• Schilling U, Dingemanse J, Ufer M. Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists. Clin Pharmacokinet. 2020;59(5):545–566.
   PubMed Web of Science ®Google Scholar
• Sinnaeve P, Fahrni G, Schelfaut D, et al.. Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. J Am Coll Cardiol. 2020;75(20):2588–2597. DOI:10.1016/j.jacc.2020.03.059.
   PubMed Web of Science ®Google Scholar
• Frossard M, Fuchs I, Leitner JM, et al.. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110(11):1392–1397. DOI:10.1161/01.CIR.0000141575.92958.9C.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010;74(4):597–607.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, et al.. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246–251.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Alexopoulos D, et al.. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2019;12(16):1521–1537. DOI:10.1016/j.jcin.2019.03.034.
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73(15):1681–1709.
   PubMed Web of Science ®Google Scholar
• Husted S, Van Giezen JJ. Ticagrelor: The First Reversibly Binding Oral P2Y 12 Receptor Antagonist. Cardiovasc Ther. 2009;27(4):259–274.
   PubMed Web of Science ®Google Scholar
• Niitsu Y, Jakubowski JA, Sugidachi A, et al.. Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y 12 Receptor Antagonist Activity. Semin Thromb Hemost. 2005;31(2):184–194.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al., Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 357(20): 2001–2015. 2007. . 10.1056/NEJMoa0706482.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al., Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 361(11): 1045–1057. 2009. . 10.1056/NEJMoa0904327.
   PubMed Web of Science ®Google Scholar
• Schupke S, Neumann FJ, Menichelli M, et al., Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 381(16): 1524–1534. 2019. . 10.1056/NEJMoa1908973.
   PubMed Web of Science ®Google Scholar
• Menichelli M, Neumann F-J, Ndrepepa G, et al.. Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes: Results From a Randomized Trial. Ann Intern Med. 2020;173(6):436–444. DOI:10.7326/M20-1806.
   PubMed Web of Science ®Google Scholar
• Aytekin A, Ndrepepa G, Neumann FJ, et al.. Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation. 2020;142(24):2329–2337. DOI:10.1161/CIRCULATIONAHA.120.050244.
   PubMed Web of Science ®Google Scholar
• Mayer K, Bongiovanni D, Karschin V, et al.. Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial. J Am Coll Cardiol. 2013;61(21):2569–2571. DOI:10.1016/j.jacc.2020.09.586.
   Google Scholar
• Zhang H, Zhang P, Dong P, et al.. Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis. Coron Artery Dis. 2018;39(7):597–604. DOI:10.1097/MCA.0000000000000541.
   Google Scholar
• Van Der Hoeven NW, Janssens GN, Everaars H, et al.. Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial. J Am Heart Assoc. 2020;9(5):e014411. DOI:10.1161/JAHA.119.014411.
   PubMed Web of Science ®Google Scholar
• Dayoub EJ, Seigerman M, Tuteja S, et al.. Trends in Platelet Adenosine Diphosphate P2Y 12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016. JAMA Intern Med. 2018;178(7):943–950. DOI:10.1001/jamainternmed.2018.0783.
   PubMed Web of Science ®Google Scholar
• Rollini F, Franchi F. The Conundrum of Platelet P2Y12 Inhibition in ST-Segment Elevation Myocardial Infarction. Circ J. 2016;80(12):2429–2431.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Gkizas V, et al.. Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment–Elevation Myocardial Infarction. Circ Cardiovasc Interv. 2004;110(6):797–804. DOI:10.1161/CIRCINTERVENTIONS.112.972323.
   Google Scholar
• Alexopoulos D, Gkizas V, Patsilinakos S, et al.. Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI. J Am Coll Cardiol. 2013;62(10):940–941. DOI:10.1016/j.jacc.2013.05.021.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Makris G, Xanthopoulou I, et al.. Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: pharmacodynamic study. Circ Cardiovasc Interv. 2014;7(2):233–239. DOI:10.1161/CIRCINTERVENTIONS.113.001118.
   PubMed Web of Science ®Google Scholar
• Haghbayan H, Deif B, Coomes EA. Chewed or Crushed Administration of Adenosine Diphosphate Receptor Inhibitors in Acute Coronary Syndromes: a Systematic Review and Meta-analysis of Randomized Controlled Trials. Cardiovasc Drugs Ther. 2020;34(1):139–142.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Barampoutis N, Gkizas V, et al.. Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. Clin Pharmacokinet. 2016;55(3):359–367. DOI:10.1007/s40262-015-0320-0.
   PubMed Web of Science ®Google Scholar
• Parodi G, Xanthopoulou I, Bellandi B, et al.. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015;65(5):511–512. DOI:10.1016/j.jacc.2014.08.056.
   PubMed Web of Science ®Google Scholar
• Rollini F, Franchi F, Hu J, et al.. Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention. J Am Coll Cardiol. 2019;12(17):1994–2004. DOI:10.1016/j.jacc.2016.02.045.
   Google Scholar
• Asher E, Tal S, Mazin I, et al.. Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial. JAMA Cardiol. 2017;2(12):1380–1384. DOI:10.1001/jamacardio.2017.3868.
   PubMed Web of Science ®Google Scholar
• Vlachojannis GJ, Wilschut JM, Vogel RF, et al., Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment–Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention. Circulation. 142(24): 2316–2328. 2020. . 10.1161/CIRCULATIONAHA.120.051532.
   PubMed Web of Science ®Google Scholar
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.
   PubMedGoogle Scholar
• Khan N, Cox AR, Cotton JM. Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review. Thromb Res. 2016;143:141–148.
   PubMed Web of Science ®Google Scholar
• Giannopoulos G, Deftereos S, Kolokathis F, et al.. 12 Receptor Antagonists and Morphine: A Dangerous Liaison?. Circ Cardiovasc Interv. 2016;9(9):9.
   Web of Science ®Google Scholar
• Kubica J, Adamski P, Ostrowska M, et al.. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37(3):245–252. DOI:10.1093/eurheartj/ehv547.
   PubMed Web of Science ®Google Scholar
• Iglesias JF, Valgimigli M, Carbone F, et al.. Effects of Fentanyl Versus Morphine on Ticagrelor-Induced Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: The PERSEUS Randomized Trial. Circulation. 2020;142(25):2479–2481.
   PubMed Web of Science ®Google Scholar
• Tavenier AH, Hermanides RS, Ottervanger JP, et al.. Impact of opioids on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial. Eur Heart J Cardiovasc Pharmacother. 2019. DOI:10.1093/ehjcvp/pvaa095.
   Google Scholar
• Saad M, Meyer-Saraei R, De Waha-thiele S, et al.. Impact of Morphine Treatment With and Without Metoclopramide Coadministration on Ticagrelor-Induced Platelet Inhibition in Acute Myocardial Infarction: The Randomized MonAMI Trial.. Circulation. 2020;141(16):1354–1356. DOI:10.1161/CIRCULATIONAHA.119.042816.
   PubMed Web of Science ®Google Scholar
• Holm M, Tornvall P, Henareh L, et al.. The MOVEMENT Trial. J Am Heart Assoc. 2019;8(2):e010152. DOI:10.1161/JAHA.118.010152.
   PubMed Web of Science ®Google Scholar
• Zwart B, Yazdani M, Ow KW, et al.. Use of glycoprotein IIb/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarction. Platelets. 2020;31(2):174–178. DOI:10.1080/09537104.2019.1665642.
   PubMed Web of Science ®Google Scholar
• Sumaya W, Parker WAE, Fretwell R, et al.. Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study). Thromb Haemost. 2018;118(7):1250–1256. DOI:10.1055/s-0038-1657768.
   PubMed Web of Science ®Google Scholar
• Sumaya W, Parker WAE, Judge HM, et al.. Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. Platelets20201–510.1038/nrcardio.2014.104
   PubMed Web of Science ®Google Scholar
• Zanchin T, Temperli F, Karagiannis A, et al.. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry. Circ Cardiovasc Interv. 2018;11(5):e006132. DOI:10.1161/CIRCINTERVENTIONS.117.006132.
   PubMed Web of Science ®Google Scholar
• Koskinas KC, Zanchin T, Klingenberg R, et al.. Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction.. J Am Heart Assoc. 2018;7(8):7. DOI:10.1161/JAHA.117.008085.
   Web of Science ®Google Scholar
• Zeymer U, Cully M, Hochadel M. Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry. Eur Heart J Cardiovasc Pharmacother. 2018;4(4):205-210. DOI: 10.1093/ehjcvp/pvy018.
   Google Scholar
• Motovska Z, Hlinomaz O, Miklik R, et al., Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study. Circulation. 134(21): 1603–1612. 2016. . 10.1161/CIRCULATIONAHA.116.024823.
   PubMed Web of Science ®Google Scholar
• Motovska Z, Hlinomaz O, Kala P, et al.. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor. J Am Coll Cardiol. 2018;71(4):371–381. DOI:10.1016/j.jacc.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Claassens DM, Sibbing D. De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature. J Clin Med. 2020;9(9):2983. DOI: 10.3390/jcm9092983.
   Google Scholar
• Cuisset T, Deharo P, Quilici J, et al.. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38(41):3070–3078. DOI:10.1093/eurheartj/ehx175.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Jacobshagen C, et al.. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747–1757. DOI:10.1016/S0140-6736(17)32155-4.
   PubMed Web of Science ®Google Scholar
• Claassens DMF, Vos GJA, Bergmeijer TO, et al.. A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI. N Engl J Med. 2019;2(17):1621–1631. DOI:10.1056/NEJMoa1907096.
   Google Scholar
• Pereira NL, Farkouh ME, So D, et al.. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA. 2020;324(8):761–771. DOI:10.1001/jama.2020.12443.
   PubMed Web of Science ®Google Scholar
• Khan SU, Singh M, Valavoor S, et al.. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. Circulation. 2020;142(15):1425–1436. DOI:10.1161/CIRCULATIONAHA.120.046308.
   PubMed Web of Science ®Google Scholar
• Wiebe J, Ndrepepa G, Kufner S, et al.. Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2021;10(2):e018304. DOI:10.1161/JAHA.120.018304.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Cho JY, Kim BK, et al.. Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction. JACC Cardiovasc Interv. 2021;14(4):431–440. DOI:10.1016/j.jcin.2020.11.036.
   PubMed Web of Science ®Google Scholar
• Levine GN, Jeong YH, Goto S, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11:597–606.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Huber K, Mehran R, et al.. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI. J Am Coll Cardiol. 2019;74(1):83–99. DOI:10.1016/j.jacc.2019.05.016.
   PubMed Web of Science ®Google Scholar
• Gargiulo G, Cannon CP, Gibson CM, et al.. Safety and efficacy of double versus triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of NOAC-based randomized clinical trials. Eur Heart J Cardiovasc Pharmacother. 2020;29:pvaa116. DOI: 10.1093/ehjcvp/pvaa116.
   Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Bhatt DL, Oldgren J, et al.. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017;377(16):1513–1524. DOI:10.1056/NEJMoa1708454.
   PubMed Web of Science ®Google Scholar
• Oldgren J, Steg PG, Hohnloser SH, et al.. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019;40(19):1553–1562. DOI:10.1093/eurheartj/ehz059.
   PubMed Web of Science ®Google Scholar
• Morici N, Savonitto S, Ferri LA, et al.. Outcomes of Elderly Patients with ST-Elevation or Non-ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Am J Med. 2019;132(2):209–216. DOI:10.1016/j.amjmed.2018.10.027.
   PubMed Web of Science ®Google Scholar
• Savonitto S, Ferri LA, Piatti L, et al.. Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization. Circulation. 2018;137(23):2435–2445. DOI:10.1161/CIRCULATIONAHA.117.032180.
   PubMed Web of Science ®Google Scholar
• Danchin N, Lettino M, Zeymer U, et al.. Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. Eur Heart J Cardiovasc Pharmacother. 2016;2(3):152–167. DOI:10.1093/ehjcvp/pvw003.
   PubMed Web of Science ®Google Scholar
• Montalto C, Morici N, Munafo AR, et al.. Optimal P2Y12 inhibition in older adults with acute coronary syndromes: A network meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2020. DOI:10.1093/ehjcvp/pvaa101.
   PubMedGoogle Scholar
• Erlinge D, Ten Berg J, Foley D, et al.. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol. 2012;60(20):2032–2040. DOI:10.1016/j.jacc.2012.08.964.
   PubMed Web of Science ®Google Scholar
• Erlinge D, Gurbel PA, James S, et al.. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol. 2013;62(7):577–583. DOI:10.1016/j.jacc.2013.05.023.
   PubMed Web of Science ®Google Scholar
• Cayla G, Cuisset T, Silvain J, et al.. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016;388(10055):2015–2022. DOI:10.1016/S0140-6736(16)31323-X.
   PubMed Web of Science ®Google Scholar